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duration of antibiotic treatment was not less than 6 
weeks and some patients received antibiotics for more 
than 6 months, probably because the prothesis was 
not removed. Where data were presented, outcome 
appeared to be favorable with appropriate antibiotic 
treatment, together with prosthetic removal (four cases), 
revision of arthroplasty or surgical drainage (four cases). 
A fatal outcome was not recorded in any of the cases. 
In the prewnt case, the severe gastroduodenal 
lesions caused by non-steroidal anti-inflammatory agents 
may have allowed the passage of the bacteria through 
the abnormal gastric membranes. The association of 
gastroduodenal ulcers and listeriosis is unusual and has 
never been reported in the literature. We suggest that 
age and diabetes mellitus, in addition to gastroduodenal 
lesions resulted in an asymptomatic L. tmwzocytogenes 
bacteremia which seeded the arthritic knee joint. 
Acknowledgments 
We thank J. McLauchlin for reading and correcting the 
manuscript. 
Laureut Mereghetti  I ,  
Natl ialie Marquet-van der iUee I ,  
Patrice Lauda t  ', Joelle Loulevgue ', 
'Laboratoire de Bactt-riologie 
et d'Hygi6ne Hospitali6i-e, 
'Service de Rhumatologie, 
H6pital Trousseau, 
CHU de Tours, 
Tours. France 
Jacques Jeannou2,  A n d &  Audur iev  
Accepted 28 October 1997 
References 
1. Newman JH,  Waycott S, Cooney LM. Arthritis due to 
Listeria monocytogenes. Arthritis Rheum 1979, 22: 1139-40. 
2. Beckenridge RL,  Buck L, Tooley E, Douglas GW Listeria 
nronorytogenes septic arthritis. Am J Clin Pathol 1980; 73: 
140-1. 
3. Wilson APK, Prouse PJ, Gumpel JM. Listeria monoryt~;qenrs 
septic arthritis following intra-articular yttrium-90 therapy. 
Ann Rheum Dis 1984; 43: 518-19. 
4. Abadie SM, Dalovisio JR, Pankey GA, Cortez LM. Listrria 
monorytogenes arthritis in a renal transplant recipient. J Infect 
Dis 1987; 156: 413-14. 
5. Arathoon E, Goodman SB, Vosti KL. Prosthetic hip infection 
caused by Listeria monocytogenes. J Infect Dls 1988; 157: 
6. C h i r p i n  K, Gleigh S. Listrria monorytogenes osteomyelitis. 
7. Curosh NA, Perednia DA. Listeria monocytogenes septic 
arthritis: a case report and review of the literature. Arch 
Intern Med 1989; 149: 1207-8. 
1282-3. 
Arch Intern Med 1989; 149: 931-2. 
8. Booth LV, Walterc MT, Tuck AC, Luqmani KA, Cawley 
MID, Listeria nionorytog,gmcs infection in a proqthetic knee 
joint in rheumatoid arthritis. Ann Rheum Dis 1990; 49: 
58-9. 
9. Massarotti EM, Dinerman H.  Septic arthritis due to Listerin 
r~ionocyto~enes: report .ind review of the literature. J Rheu- 
matol 1990; 17: 111-13. 
10. Weiler Pj, Hastings DE. Lirtrrin r~ionocytop~r.s--nn unusual 
cause of late infection in a procthetic hip joint. J Rheumatol 
11. Thangkhiew I, Ghoshn MK, Kar NK, Robinson PJ. Septic 
arthritis due to Lictrrin rnonorytiigenes. J Infect 1990; 21: 
324-5. 
12. McLauchlin J, Audurier A, Taylor AG. Treatment failure and 
recurrent human listeriosis. J Antimicrob Chemother 1991 ; 
13. Robins R H C ,  Brunton WA. Listeria infection in an old hip 
iinplaiit. Int Orthop 1992; 16: 235-6. 
14. Allerberger F, Karten MJ, Cockerill F R  I l l ,  Kricmer M, 
Dierich MP. Listrria r i ~ o n i i c y f q e t i ~ ~  infection in prosthetic 
joints. Int Orthop 1992; 16: 237-9. 
15. Ellis LC, Segreti J, Gitehq S, Huber jF. Joint infection due to 
Listeria morrocytcpwer: caw report and review Cliri Infect llis 
16. Ukkonen HJ, Vuori KP, Lehtonen OP, Kotilaineri PM. 
Listeria nionocytogenrs arthritis of several jointy. Scarid J 
Kheumatol 1995; 24: 392-4. 
1990; 17: 705-7. 
27: 851-7. 
1995; 20: 1548-50. 
Escherichia coli producing a cephamycinase (CMY-2) 
from a patient from the Libyan-Tunisian border region 
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Among Enterobacteriaceae, Eschericlzia coli is usually 
susceptible to a broad variety of antibiotics. However, 
strains producing extended spectrum P-lactamases 
(ESBLs) have been increasingly described during the 
past decade, mainly in North and South America and 
Europe [1,2]. We recently encountered a multiply- 
resistant ESBL-producing E. coli, with resistance to 
ceftriaxone as a hallmark, in a patient transferred from 
Libya (North Africa) to Switzerland. Because little 
is known about the epidemiology of resistance to 
p-lactams in this area, we decided to analyze the 
mechanism in this isolate. 
A 57-year-old European male passenger was 
struck unconscious and severely traumatized (temporal 
impression fracture, serial rib fractures, pneumo- 
hemothorax with emphysema) in a car accident near 
Sobrata, Libya, on 29 November, 1996. He was 
given emergency care at a local hospital (Sobrata), 
and after stabilization of his vital signs he was trans- 
ferred to Djerba, Tunisia. Initial antibacterial medica- 
tion included ceftriaxone (1 g b i d .  IV), gentamicin 
(80 mg/kg t.i.d. IV), and metronidazole (500 nig t.i.d. 
Concise C o m m u n i c a t i o n s  169 
IV). His condition improved within a few days, 
allowing for his repatriation by air ambulance on 3 
December, 1996. On his arrival at the Basei University 
Clinics, his clinical status had deteriorated. He was 
thought to be septic and was transferred to the surgical 
intensive care unit. Two blood cultures grew E. coli 
susceptible to ceftriaxone, and a single tracheal aspirate 
yielded E. coli classified as intermediately susceptible 
to ceftriaxone. The antibiotic therapy was changed 
to imipenem (500 mg q.i.d. IV) plus tobramycin 
(120 mg/kg b.i.d. IV). However, because of persistently 
elevated blood leukocyte counts (30-43 x 109/L) and 
C-reactive protein (> 500 mg/L), antibacterial therapy 
was further changed to ciprofloxacin (400 mg b.i.d. IV). 
Thereafter, the patient improved steadily. On 6 January 
1997 he was discharged to a long-term care facility to 
continue ongoing rehabilitation. 
We hypothesized that the initially poor response to 
the antibiotic regimens might have been due to the 
multiresistant E. coli strain fiom the respiratory tract, 
and that this might produce an ESBL. We attempted to 
further characterize the mechanism of resistance to the 
p-lactams and the location and transferability of the 
gene responsible for ths. 
Our results demonstrated resistance both of the 
wild-type E. coli LyHo and the transconjugant strain 
to a broad spectrum of p-lactams, including cefoxitin, 
but not the carbapenems and cefepime (Table 1). 
Addition of various p-lactamase inhibitors gave only 
a moderate enhancement of the antibacterial activity 
of the p-lactam partner. Resistance to p-lactams and 
gentamicin was transferable into E. coli C600 at a 
frequency of 4 . 5 ~ 1 0 - ~  per donor cell. Crude homo- 
genates of both the wild-type and the transconjugant 
strain were submitted to isoelectric focusing and 
demonstrated a nitrocefin-hydrolyzing band at a PI of 
9.0, as shown previously for the CMY-2 enzyme [3]. 
At this PI, cefoxitin was hydrolyzed. From this we 
deduced that the strain E. coli LyHo would produce 
a plasmid-encoded cephamycinase. To further sub- 
stantiate this assumption, oligonucleotide primers 
specific for the b l u c ~ ~ - 2  gene were used to ampli$ a 
430-bp fragment of the blu gene. The PCR product 
was sequenced and shown to be identical in its 
nucleotide sequence to the corresponding part of the 
original b l a ~ ~ y - 2  gene [3]. Thus, the molecular data 
confirmed that the E. coli isolate of the patient fiom 
Libya carries a plasmidic blu gene similar to that isolated 
6 years before (1990) in Klebsiellupncumoniae HEL-1 in 
Athens [3]. 
Since 1989 [4] plasmidic cephamycinase genes 
have been identified in various regr,ons of the world. 
There appears to be a clustering of cephamycinase types 
according to geographic regions, with CMY-2 being 
Table 1 Antibiotic susceptibdity of E. coli LyHo, its transconjugant E. coli C600 R+ (E. coli LyHo), the CMY-2-producing 
transconjugant E. coli C600 R+ (K. pneulnoniae HEL-1) and the E. coli C600 R- recipient 
MIC (mg/L) 
E. coli C600 R’ E. coli C600 R+ 
Antibiotic E. coli LyHo (E. coli LyHo) (K. pneumoniae HEL-1) .E. coli C600 R- 
Cefomtin 
+ Clavulanate 
+ Sulbactam 
+ Tazobactam 
Cefotetan 
Latamoxef 
Flomoxef 
Ceftriaxone 
Cefotaxime 
Ceitazidime 
Cefepime 
Ceftibuten 
Aztreonam 
Piperacillin 
Teniocillin 
Imipenem 
Meropenem 
Ciprofloxacin 
Gentamicin 
Tobramycin 
+ Tazobactarn 
256 
128 
32 
64 
128 
16 
32 
128 
128 
128 
1 
1024 
64 
128 
32 
8 
0.25 
0.06 
0.06 
16 
32 
128 
64 
32 
32 
64 
8 
16 
64 
64 
128 
1024 
64 
128 
32 
8 
0.25 
0.06 
0.016 
8 
16 
0.5 
256 
128 
32 
64 
64 
2 
32 
32 
16 
128 
512 
64 
256 
64 
8 
0.06 
0.016 
8 
128 
0.5 
0.5 
4 
2 
2 
2 
0.13 
0.13 
0.06 
0.06 
0.03 
0.13 
0.03 
0.25 
0.06 
1 
1 
8 
0.25 
0.06 
0.016 
0.13 
0.13 
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predominant in the Mediterranean area [5]. This 
finding suggests ongoing spread and/or emergence 
of cephamycinase genes, and underscores the necessity 
of monitoring multiply-resistant strains in order to 
minimize the risk of therapeutic failure due to 
resistance against established antibiotic combinations, 
e.g. a third-generation cephalosporin plus an amino- 
glycoside. 
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Comparative activities of amoxycillin and 10 other 
oral drugs against penicillin-susceptible and -resistant 
Streptococcus pneumoniae strains recently isolated 
in Italy 
Clin Mirrobiol infect 1998; 4: 170-173 
Streptococcus pneumoniae remains a leading cause of 
morbidity and mortality despite the availability of 
several antimicrobial agents that perform adequately in 
vitro. This pathogen is known to cause a broad 
spectrum of infections, with pneumonia, otitis media, 
septicemia and meningitis being the most common 
[1,21. The incidence of penicillin-resistant, multiply- 
resistant pneumococci is increasing worldwide. 
Although for non-meningitic infections high-dose 
penicillin remains clinically effective against strains that 
are resistant in vitro, this type of treatment is risky and 
may not aIways be successful [3,4]. Previous studies 
[5,6] have demonstrated that amoxycdlin can display 
useful potency in vitro against penicillin-resistant 
pneumococci. In order to confirm this finding in the 
pneumococcal population circulating in Italy, the in 
vitro activities of amoxycillin and amoxycillin/ 
clavulanate in comparison with those of other oral 
antibiotics has been assessed on a substantial number of 
strains. 
A total of 798 Streptococcus pneumoniae strains, 
including 49 penicillin-resistant strains (29 displaying 
low- and 20 high-level resistance according to the 
breakpoints specifically proposed for S. pneurnoniae by 
the National Committee for Clinical Laboratory 
Standards (NCCLS) [7] (see also footnote 'a' in Table l),  
isolated from 1993 to 1996 in nine laboratories in 
central and northern Italy (Genoa, Parma, Berganio, 
Turin, Perugia, Vercelli, Bologna, Florence and Milan) 
were tested. Consecutive pneumococcal strains (with 
duplicate isolates from same patient episodes excluded) 
from all sites were dispatched to the Institute of 
Microbiology of Genoa, where the microorganisms 
were stored in 10% glycerol at -70°C. The in vitro 
activity of selected antibiotics against all strains was 
studied at the same time after subculturing the micro- 
organisms twice on blood agar plates. s. pneumoniae 
ATCC 49619 was included as control strain. 
Amoxycillin and clavulanic acid (used in associa- 
tion in the ratio 2 : 1) were obtained from SmithKline 
Beecham Pharmaceuticals (Milan, Italy). Cefixime, 
cefaclor, erythromycin, clarithromycin, azithromycin, 
co-trimoxazole, ofloxacin and ciprofloxacin were 
supplied by their respective manufacturers. Minimal 
inhibitory concentrations (MICs) were determined by 
microdilution assay in cation-adjusted Mueller-Hinton 
broth with 5% lysed horse blood, as detailed in the 
NCCLS [7] guidelines. 
Under these experimental conditions, clavulanic 
acid did not decrease the MIC values of amoxycillin, as 
reported elsewhere for penicillin [ 8 ] .  
Against the 749 penicillin-susceptible S. przerr- 
moniae isolates amoxycillin showed the highest activity 
in terms of MICro (0.06 mg/L), while the comparative 
agents displayed MIC9o values (mg/L) ranging from 0.5 
for cefixime to 8 for co-trimoxazole (Table 1). The in 
vitro potency of amoxycillin was also confirmed when 
the data were translated into percentages of susceptible 
strains. The two drugs inhibited, in fact, 100% of the 
isolates tested, while the comparator agents were 
efficacious on 80% (co-trimoxazole) or 89% (erythro- 
mycin, clarithromycin, azithromycin) of the penicillin- 
susceptible strains. 
